Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

300676.SZ

HOLDREMOVE

BGI Genomics Co., Ltd. · Healthcare · China · $2.3B · Avg Vol: $39M/d

37
StockRank
Q
43
V
48
M
38
P/E (TTM)
—
ROE
-6.7%
D/E
0.1x
Dividend %
—
Director Trades · 180d
None in 180d →
Buybacks · 180d
$55.4M · 1d →
AI CONVICTION THESIS

BGI Genomics faces severe geopolitical headwinds, particularly from US legislative actions targeting Chinese biotech entities (e.g., the Biosecure Act). This creates an asymmetric downside risk that overrides its underlying genomic sequencing capabilities.

COMPANY DESCRIPTION

BGI Genomics Co., Ltd. provides scientific research and clinical genetic testing services, specializing in prenatal screening, oncology diagnostics, and infectious disease identification. The company's competitive moat is built on its massive genomic sequencing throughput, proprietary sequencing platforms, and extensive clinical databases. It is a globally prominent genomics leader, driving down the cost of genetic testing through vertical integration and scale.

FINANCIAL SUMMARY (USD)

Year2022202320242025CAGR
Revenue1.0B643M572M548M-19.3%
EPS0.290.03-0.32-0.22-88.4%
Shares414M414M416M418M+1.1%
Debt140M162M70M95M-12.2%
Equity1.5B1.5B1.4B1.3B-5.5%
Op CF19M60M14M-9M-14.5%
Inv CF-86M-259M-46M-152M—
Fin CF-177M-39M-101M22M—
Loading...
PRICE (1M)-17.7%
4.865.315.756.196.64May 8May 29Jun 18
SMA 50SMA 200
Close
$5.24
RSI (14)
42.6
52W High
$9.61
From 52W High
0.5%

SCORE BREAKDOWN

Quality
43
ROIC
-6.1%37.8
ROE
-6.7%37.9
GP/Assets
11.1%28.1
Op. Margin
-2.8%33.2
FCF/Assets
-2.7%41.5
Piotroski
—55.7
Int. Cover
-15.7x21.3
D/E Ratio
0.07x70.7
Current Ratio
2.60x47.5
Value
48
P/E (TTM)
—N/A
EV/EBITDA
-216.4x98.2
P/FCF
—N/A
P/B
1.7x61.8
P/S
3.7x49.6
Div Yield
—N/A
Momentum
38
52W High %
55%30.0
RS 6M
-30%41.8
SMA 50/200
0.84x20.1
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
+112%75.2
Q Growth
—N/A

FUNDAMENTALS

Market Cap
$2.3B
P/E (Forward)
213.1x
Gross Margin
33.8%

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 300676.SZ are excluded.

TickerCompanyMkt CapStockRankSignal
300676.SZBGI Genomics Co., Ltd.(you)$2.3B37HOLD
3347.HKHangzhou Tigermed Consulting Co., Ltd$3.4B41HOLD
300463.SZMaccura Biotechnology Co.Ltd$845M33SELL
603108.SSShanghai Runda Medical Technology Co., Ltd.$1.1B21SELL
603716.SSThalys Medical Technology Group Corporation$568M31SELL
2427.HKGuanze Medical Information Industry (Holding) Co., Ltd.$526M42HOLD
603882.SSGuangzhou Kingmed Diagnostics Group Co., Ltd.$1.8B67BUY
2268.HKWuXi XDC Cayman Inc.$8.8B47HOLD
9860.HKAdicon Holdings Limited$394M32SELL
6127.HKJoinn Laboratories(China)Co.,Ltd.$1.7B77BUY

Peer medians: ROE 4.8% · P/E 27.8x · Gross margin 53.1%

BGI Genomics Co., Ltd. (300676.SZ) — Stock Score Summary

BGI Genomics Co., Ltd. (300676.SZ) has a MoatMap StockRank of 37/100 based on Quality (43/100), Value (48/100), and Momentum (38/100) factor scores. The current signal is HOLD. BGI Genomics faces severe geopolitical headwinds, particularly from US legislative actions targeting Chinese biotech entities (e.g., the Biosecure Act). This creates an asymmetric downside risk that overrides its underlying genomic sequencing capabilities.

BGI Genomics Co., Ltd. provides scientific research and clinical genetic testing services, specializing in prenatal screening, oncology diagnostics, and infectious disease identification. The company's competitive moat is built on its massive genomic sequencing throughput, proprietary sequencing platforms, and extensive clinical databases. It is a globally prominent genomics leader, driving down the cost of genetic testing through vertical integration and scale.

Key Financial Metrics

Price$5.24
Market Cap$2.3B
P/E (Forward)213.13
Price/Book1.68
Return on Equity-6.7%
Return on Invested Capital-6.1%
Debt/Equity7.07
Gross Margin33.8%
Operating Margin-2.8%
Revenue Growth20.4%
Free Cash Flow$-7M

BGI Genomics Co., Ltd. operates in the Diagnostics & Research industry, part of the Healthcare sector (China).

Frequently Asked Questions

What is BGI Genomics Co., Ltd.’s (300676.SZ) StockRank?
MoatMap’s StockRank for BGI Genomics Co., Ltd. (300676.SZ) is 37/100, with a Hold signal. It is a composite of Quality (43), Value (48), and Momentum (38) factor ranks across MoatMap’s 20,000+ stock universe.
Does BGI Genomics Co., Ltd. have an economic moat?
BGI Genomics Co., Ltd. (300676.SZ) has a Quality factor score of 43/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is BGI Genomics Co., Ltd. a buy, hold, or sell?
MoatMap’s current signal for BGI Genomics Co., Ltd. (300676.SZ) is Hold, based on a StockRank of 37/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is BGI Genomics Co., Ltd. in?
BGI Genomics Co., Ltd. (300676.SZ) operates in the Healthcare sector, specifically the Diagnostics & Research industry (China).
Browse all ranked stocks300676.SZ deep dive reportAI ChampionsHow we score stocksSense-check another stock